Pharma BD Deal Intelligence

BioMarin Pharmaceutical Inc. / Inozyme Pharma, Inc.

2025 · Acquisition/Merger · $270M · Complete

BioMarin agreed to acquire Inozyme Pharma for $4.00 per share in cash, total consideration of approximately $270 million, adding INZ-701, a Phase 3 enzyme replacement therapy for ENPP1 Deficiency, to BioMarin's enzyme therapy business. BioMarin guided to a first pivotal data readout in children in early 2026 and potential launch in 2027. The tender offer commenced June 2, 2025 and expired June 30, 2025 with approximately 70% of shares tendered; the acquisition subsequently closed.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals  ·  Rare Disease deals